Xanthinuria – Comprehensive Medical Guide

Overview

Xanthinuria is a rare inherited metabolic disorder in which the body cannot properly break down purines, leading to a buildup of xanthine in the blood and urine. The condition results from a deficiency of the enzyme xanthine oxidase (or, less commonly, aldehyde oxidase), which normally converts hypoxanthine to xanthine and xanthine to uric acid.

• Population affected: Both males and females are equally susceptible because the disorder is autosomal recessive.
• Prevalence: Estimated at 1–2 per 100,000 individuals worldwide, though exact numbers are uncertain due to under‑diagnosis.^{[1] NIH Genetic and Rare Diseases Information Center}
• Types:
  • Type I – deficiency of xanthine oxidase (most common).
  • Type II – deficiency of both xanthine oxidase and aldehyde oxidase.

Symptoms

The clinical picture varies from completely asymptomatic to severe renal complications. Below is a comprehensive list of reported manifestations:

Renal symptoms

• Kidney stones (xanthine calculi): The most frequent problem; stones are radiolucent on plain X‑ray, often discovered after flank pain.
• Hematuria: Blood in the urine caused by stone irritation.
• Flank or abdominal pain: Cramping that may be intermittent or colicky.
• Recurrent urinary tract infections: Secondary to obstruction.
• Chronic kidney disease: Progressive loss of renal function if stones are not managed.

Systemic symptoms

• Low uric acid levels (hypouricemia): Often an incidental laboratory finding.
• Fatigue or weakness: May reflect chronic kidney stress.
• Muscle cramps: Rare, related to electrolyte shifts.

Rare presentations

• Gout‑like arthralgia: Very uncommon because uric acid is low.
• Neurologic signs: In rare cases of severe xanthine accumulation, patients have reported headaches or mild confusion.

Causes and Risk Factors

Xanthinuria is a genetic disorder, but understanding the underlying biochemistry helps clarify risk.

Genetic cause

• Mutations in the XDH gene (chromosome 2p23) cause xanthine oxidase deficiency (type I).
• Mutations in the MOCOS gene (chromosome 18q12) affect the molybdenum cofactor required for both xanthine oxidase and aldehyde oxidase, producing type II.
• Both are inherited in an autosomal recessive pattern – two carrier parents have a 25 % chance of having an affected child.

Non‑genetic contributors

• Consanguinity: Higher prevalence in families where close relatives have children.
• Diet high in purines: Increases xanthine production, worsening stone formation.
• Dehydration: Concentrates urine, facilitating stone precipitation.

Who is at higher risk?

• Individuals of Middle Eastern, Mediterranean, or South Asian descent, where certain founder mutations have been reported.^{[2] European Journal of Human Genetics}
• People with a sibling diagnosed with xanthinuria.
• Patients with unexplained low serum uric acid and recurrent radiolucent stones.

Diagnosis

Because symptoms overlap with other stone diseases, a systematic approach is essential.

History & physical examination

• Document family history of renal stones or known metabolic disorders.
• Assess hydration status, dietary habits, and medication use (e.g., allopurinol, which can mask uric acid patterns).

Laboratory tests

• Serum uric acid: Typically < 2 mg/dL (normal 3–7 mg/dL).
• Serum xanthine and hypoxanthine: Elevated levels measured by high‑performance liquid chromatography (HPLC) or mass spectrometry.
• Urine analysis: High xanthine concentration; urine pH is usually neutral.
• Kidney function panel: BUN, creatinine, electrolytes to assess renal impact.

Imaging studies

• Non‑contrast CT scan: Gold standard for detecting radiolucent xanthine stones.
• Ultrasound: Useful in pregnancy or children to avoid radiation.
• Plain abdominal X‑ray: Often negative because xanthine stones are radiolucent.

Genetic testing

Sequencing of XDH and MOCOS confirms the diagnosis and informs family counseling. Many commercial labs offer targeted panels for hereditary stone diseases.

Differential diagnosis

• Uric acid stones (radiolucent but different chemistry).
• Cystinuria (also radiolucent, but presents with cystine crystals).
• Medication‑induced stones (e.g., from sulfamethoxazole).

Treatment Options

Management aims to prevent stone formation, preserve kidney function, and address any existing stones.

Dietary modifications

• Low‑purine diet: Limit red meat, organ meats, seafood, legumes, and high‑fructose corn syrup.
• Increase fluid intake: Aim for at least 2.5–3 L of urine output per day (≈ 3–4 L of fluid), spread throughout the day.
• Alkalinization: Not routinely required because xanthine is neutral, but bicarbonate may help if urine is acidic.

Pharmacologic therapy

• Allopurinol or febuxostat: NOT recommended; they inhibit xanthine oxidase further, worsening xanthine accumulation.
• Potassium citrate: May be used to increase urine volume and maintain a slightly alkaline environment, reducing stone risk.
• Hydration agents: Oral rehydration solutions for patients unable to meet fluid goals.

Stone removal

• Extracorporeal shock wave lithotripsy (ESWL): Effective for stones ≤2 cm.
• Ureteroscopy with laser lithotripsy: Preferred for distal ureteral stones.
• Percutaneous nephrolithotomy (PCNL): For large or staghorn calculi.

Monitoring and follow‑up

• Serum and urine xanthine levels every 6–12 months.
• Annual renal ultrasound or CT if stone burden is high.
• Genetic counseling for the patient and at‑risk relatives.

Living with Xanthinuria

While the disorder is lifelong, most patients lead normal lives with proper management.

Practical daily tips

• Track fluid intake: Use a water‑tracking app or a marked bottle.
• Read labels: Avoid foods and drinks high in purines (e.g., yeast extracts, gravies).
• Stay active: Regular exercise promotes hydration and kidney health.
• Medication review: Inform all healthcare providers of the diagnosis; many drugs (e.g., chemotherapy agents) may interact.
• Carry a medical ID: Note “Xanthinuria – high risk for kidney stones” for emergencies.

Psychosocial considerations

• Join rare‑disease support groups (e.g., NORD, RareConnect) to connect with other families.
• Consider counseling if recurrent stone events cause anxiety or depression.

Prevention

Because the genetic defect cannot be altered, prevention focuses on reducing stone formation.

• Maintain >2 L of urine output daily; adjust for climate and activity level.
• Adopt a low‑purine diet consistently—not just during acute episodes.
• Limit alcohol and sugary beverages, both of which can promote dehydration.
• Regular follow‑up with a nephrologist or urologist familiar with metabolic stone disease.
• Screen first‑degree relatives with a simple serum uric acid test and, if low, consider genetic testing.

Complications

If left untreated or poorly managed, xanthinuria can lead to serious outcomes:

• Recurrent kidney stones: May cause chronic pain, infection, and obstruction.
• Obstructive uropathy: Acute blockage can lead to hydronephrosis and loss of renal function.
• Chronic kidney disease (CKD): Progressive loss of glomerular filtration rate (GFR) in up to 15 % of patients with frequent stones.^{[3] Kidney International}
• Rare systemic toxicity: Very high xanthine levels have been reported to cause neurologic symptoms, though this is exceedingly uncommon.

When to Seek Emergency Care

References

1. National Institutes of Health, Genetic and Rare Diseases Information Center (GARD). “Xanthinuria.” Accessed March 2024.
2. Ali, A. et al. “Founder mutations in XDH causing xanthinuria in Middle Eastern families.” European Journal of Human Genetics, 2022.
3. Foster, K. et al. “Long‑term renal outcomes in patients with hereditary xanthine stones.” Kidney International, 2021.
4. Mayo Clinic. “Kidney stones – causes, risk factors, and prevention.” Updated 2023.
5. World Health Organization. “Guidelines on management of rare metabolic disorders.” 2020.